Mabthera(Rituximab) Conc For Solution For Infusion


Indications and Reactions:

Role Indications Reactions
Primary
Non-hodgkin's Lymphoma 18.5%
B-cell Lymphoma 17.5%
Drug Use For Unknown Indication 16.2%
Chronic Lymphocytic Leukaemia 10.9%
Diffuse Large B-cell Lymphoma 9.6%
Lymphoma 9.6%
Rheumatoid Arthritis 7.6%
Systemic Lupus Erythematosus 1.8%
Mantle Cell Lymphoma 1.5%
Idiopathic Thrombocytopenic Purpura 1.0%
Neoplasm 1.0%
Autoimmune Thrombocytopenia 0.8%
Cryoglobulinaemia 0.8%
Anaemia Haemolytic Autoimmune 0.5%
Behcet's Syndrome 0.5%
Connective Tissue Disorder 0.5%
Polyarthritis 0.5%
T-cell Lymphoma 0.5%
Waldenstrom's Macroglobulinaemia 0.5%
Factor Viii Inhibition 0.3%
White Blood Cell Count Decreased 15.0%
Pulmonary Embolism 6.3%
Pulmonary Fibrosis 6.3%
Pyrexia 6.3%
Renal Failure 6.3%
Cerebrovascular Accident 5.0%
Death 5.0%
Myocardial Infarction 5.0%
Neutropenia 5.0%
Sepsis 5.0%
Thrombocytopenia 5.0%
Vomiting 5.0%
Febrile Neutropenia 3.8%
Pneumocystis Jiroveci Pneumonia 3.8%
Serum Sickness 3.8%
Tumour Lysis Syndrome 3.8%
Amyloidosis 2.5%
Ascites 2.5%
Coma 2.5%
Gamma-glutamyltransferase Increased 2.5%
Secondary
B-cell Lymphoma 71.4%
Vasculitis 28.6%
Pneumocystis Jiroveci Pneumonia 66.7%
Pyrexia 33.3%

Drug Data